INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,990
				Filing Date	October 10, 2003
				First Named Inventor	James McSwiggen
				Art Unit	1633
				Examiner Name	Janet Epps-Ford
Sheet	1	of	3	Attorney Docket Number	04-736 (400/134)

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document No. Number-Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2003/0059944	03-27-2003	Lois-Caballe et al.	
	2.	US-2003/0177507-A1	09-18-2003	Hoener et al.	
	3.	US-2003/0186920-A1	10-02-2003	Sirois	
	4.	US-2004/0001811-A1	01-01-2004	Kreutzer et al.	
	5.	US-2004/0053875-A1	03-18-2004	Kreutzer et al.	
	6.	US-2004/0161844-A1	08-19-2004	Baker et al.	
	7.	US-2004/0175703-A1	09-09-2004	Kreutzer et al.	
	8.	US-2005/0004064-A1	01-06-2005	Tei et al.	
	9.	US-2005/0260617-A1	11-24-2005	Saigo et al.	
	10.	US-2006/0275762-A1	12-07-2006	Saigo et al.	
	11.	US-2007/0166716-A1	07-19-2007	Naito et al.	
	12.	US-6,060,456-A	05-09-2000	Arnold et al.	
	13.	US-6,509,154-B1	01-21-2003	de Paillette	
	14.	US-6,831,171-B2	12-14-2004	Breaker et al.	
	15.	US-7,022,828-B2	04-04-2006	McSwiggen	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[1]
	16.	EP-1 214 945-B1	06-19-2002	Kreutzer et al.		Translation of claims only
	17.	EP-1 389 637-A1	02-18-2004	Klippel et al.		
	18.	WO-00/21560-A1	04-20-2000	Alitalo et al.		
	19.	WO-04/029212-A2,A3	04-08-2004	Rana et al.		
	20.	WO-04/090105-A2,A3	10-21-2004	Leake et al.		
	21.	WO-2004/048566-A1	06-10-2004	Saigo et al.		Translation of Abstract Only
	22.	WO-2005/049821-A1	06-02-2005	Naito et al.		Translation of Abstract Only

[1] Applicant is to place a check mark here if English language translation is attached.

Examiner Signature		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,990
				Filing Date	October 10, 2003
				First Named Inventor	James McSwiggen
				Art Unit	1633
				Examiner Name	Janet Epps-Ford
Sheet	2	of	3	Attorney Docket Number	04-736 (400/134)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T^2
	23.	Bernstein et al. "The Rest is Silence," *RNA* 7(11):1509-1521 (November 2001).	
	24. *	Branch. "A Good Antisense Molecule is Hard to Find," *TIBS* 23(2):45-50 (February 1998).	
	25. *	Downward. "RNA Interference," *BMJ* 328(7450):1245-1248 (May 22, 2004).	
	26.	GenBank Accession No. BX248289 dated June 18, 2003.	
	27. *	Hafez et al. "On the Mechanism Whereby Cationic Lipids Promote Intracellular Delivery of Polynucleic Acids," *Gene Therapy* 8(15):1188-1196 (August 2001).	
	28. *	Hannon et al. "Unlocking the Potential of the Human Genome with RNA Interference," *Nature* 431(7006):371-378 (September 16, 2004).	
	29. *	Li et al. "Delivery of RNA Interference," *Cell Cycle* 5(18):2103-2109 (September 2006; epub. September 15, 2006).	
	30. *	Lieberman et al. "Interfering with Disease: Opportunities and Roadblocks to Harnessing RNA Interference," *Trends Mol. Med.* 9(9):397-403 (September 2003).	
	31. *	Lyden et al. "Impaired Recruitment of Bone-Marrow-Derived Endothelial and Hematopoietic Precursor Cells Blocks Tumor Angiogenesis and Growth," *Nature Medicine* 7(11):1194-1201 (November 2001).	
	32. *	Opalinska et al. "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," *Nature Reviews Drug Discovery* 1(7):503-514 (July 2002).	
	33. *	Paroo et al. "Challenges for RNAi in Vivo," *Trends in Biotechnology* 22(8):390-394 (August 2004).	
	34. *	Ryther et al. "siRNA Therapeutics: Big Potential From Small RNAs," *Gene Therapy* 12(1):5-11 (January 2005).	
	35. *	Sandberg et al. "Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (Angiozyme) in Healthy Volunteers," *J. Clin. Pharmocology* 40(12, Pt. 2):1462-1469 (December 2000).	
	36. *	Sledz et al. "RNA Interference in Biology and Disease," *Blood* 106(3):787-794 (August 1, 2005; epub. April 12, 2005).	
	37. *	Strauss. "Candidate 'Gene Silencers' Found," *Science* 286(5441):886 (October 29, 1999).	
	38. *	Woessman et al. "RNA Interference: New Mechanisms for Targeted Treatment?" *Rev. Clin. Exp. Hematol.* 7(3):270-291 (September 2003).	
	39.	Hasan et al. "VEGF Antagonists," *Expert Opin. Biol. Ther.* 1(4):703-718 (July 2001).	

Examiner Signature		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,990
				Filing Date	October 10, 2003
				First Named Inventor	James McSwiggen
				Art Unit	1633
				Examiner Name	Janet Epps-Ford
Sheet	3	of	3	Attorney Docket Number	04-736 (400/134)

	40.	Kawasaki et al. "Uniformly Modified 2'-Deoxy-2'-Fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," *J. Med. Chem.* 36(7):831-841 (April 2, 1993).	
	41.	Morvan et al. "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," *J. Med. Chem.* 36(2):280-287 (January 22, 1993).	
	42.	Pavco et al. "Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors," *Clin. Cancer Res.* 6(5):2094-2103 (May 2000).	

[2] Applicant is to place a check mark here if English language translation is attached.

Examiner Signature		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.